Frontier Pharma First-In-Class Innovation in Hematological Cancers First-in-Class Innovation in Hematological Cancers | Page 5

4.7 Treatment 18
4.7.1 Surgery and Radiation Therapy 19
4.7.2 Stem-Cell Transplantation 19
4.7.3 Pharmacotherapy 20
4.8 Overview of Marketed Products 21
4.9 Current Unmet Need in the Hematological Cancer Market 22
5 Pipeline Landscape Assessment 24
5.1 Hematological Cancers Pipeline Overview 24
5.1.1 Pipeline Development Landscape 24
5.1.2 Molecular Targets in the Pipeline 25
5.1.3 Comparative Distribution of Programs between the Hematological Cancer Market and Pipeline
by Molecular Target 26
5.2 First-in-Class and Versatile Programs 26
5.2.1 First-in-Class Hematological Cancers Programs by Phase, Molecule Type and Molecular Target
26
5.2.2 Versatility of First-in-Class Pipeline Programs 30
6 Signaling Network and Innovation Alignment within Hematological Cancers 39
6.1 Complexity of Signaling Networks in Hematological cancer 39
6.2 Signaling Pathways and First-in-Class Molecular Target Integration 39
6.3 First-in-Class Matrix Assessment 40
7 First-in-Class Target Evaluation 45
7.1 Pipeline Programs Targeting Neurogenic Locus Notch Homolog Protein 1 45
7.1.1 Overview of Pipeline Programs Targeting Neurogenic Locus Notch Homolog Protein 1 46
Follow Us: